Literature DB >> 9972956

Radiologic progression in early rheumatoid arthritis treated with methotrexate.

M Maravic1, C Bologna, J P Daures, C Jorgensen, B Combe, J Sany.   

Abstract

OBJECTIVE: To evaluate radiologic progression in patients with early rheumatoid arthritis (RA) receiving methotrexate (MTX) as the first slow acting drug.
METHODS: An open, prospective study of 29 patients with RA (21 F, 8 M, mean age 48.5+/-15.4 yrs). The mean duration of RA was 6.6 (2-60) months; and rheumatoid factor was present in 11 cases. Clinical, biological, and radiographic evaluations were done before the start of MTX treatment and after 13+/-3.8 months. Radiographs of hands and wrists were blindly studied by 2 physicians, using Larsen's and modified Sharp's methods. There was a significant correlation for the scores of the 2 physicians evaluated by kappa coefficient. Radiographic evolution was defined as an increase of 15 points in the radiologic score by each method used.
RESULTS: Patients showed significant clinical improvement after one year of MTX treatment. Despite clinical and biological improvement, significant mean radiographic progression was noted, with Larsen's method (p = 0.001) and Sharp's method (p = 0.034), without reaching the maximum score. However, using the definition of radiographic progression, the radiologic scores indicated stabilization in 23 patients with Larsen's method and in 24 patients with Sharp's method.
CONCLUSION: This study revealed mild radiographic progression in early RA patients treated with MTX for one year. Further controlled studies are needed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9972956

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  The treatment of rheumatoid arthritis: a review of recent clinical trials.

Authors:  T Mikuls; L Moreland
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment.

Authors:  A S Russell; G V Wallenstein; T Li; M C Martin; R Maclean; B Blaisdell; K Gajria; J C Cole; J-C Becker; P Emery
Journal:  Ann Rheum Dis       Date:  2006-09-19       Impact factor: 19.103

3.  Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

4.  Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.

Authors:  Jeroen P Jansen; Maria-Cecilia Vieira; John D Bradley; Joseph C Cappelleri; Samuel H Zwillich; Gene V Wallenstein
Journal:  BMC Musculoskelet Disord       Date:  2016-08-18       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.